Brind.

FDA granted Fast Track and Orphan Drug designation for Tivic Health Systems, Inc. following company announcements regarding results from Fremont on August 7, 2025.

2 reports, 2 independent Updated Aug 7
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
3
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

FDA granted Fast Track and Orphan Drug designation for Tivic Health Systems, Inc. following company announcements regarding results from Fremont on August 7, 2025.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Tivic Health Systems, based in Fremont, announced that the FDA approved its VNS treatments on June 25, 2025.Sub-event
  2. FDA granted Fast Track designation for Tivic Health Systems' TLR5 agonist Entolimod, and Lisa Wolf assumed CFO role.Sub-event
  3. FDA granted Fast Track and Orphan Drug designation for Tivic Health Systems, Inc. based on Fremont results.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Business WireTivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast FREMONT, Calif., August 07, 2025--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIV
  • MedTech DiveCMS proposes covering renal denervation for hypertension This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter.